Catalyst

Slingshot members are tracking this event:

Updated data from Incyte's (INCY) Phase 1/2 ECHO-202/KEYNOTE-037 study in treating cancer with epacadostat in combination with KEYTRUDA, will be highlighted in an oral presentation on Saturday, 9 Sept 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
INCY Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 09, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Echo-20, Keynote-037, Phase 1/2 Study